World Journal of Surgery

, Volume 31, Issue 2, pp 276–289 | Cite as

Lymph Node Ratio is More Valuable than Level III Involvement for Prediction of Outcome in Node-Positive Breast Carcinoma Patients




We examined the relationship between different expressions of positive axillary lymph nodes (PN) and the outcomes of node-positive breast carcinoma patients to determine the best predictor(s) among these expressions and to assess whether anatomic high level involvement is an independent prognostic factor.

Study Design

In this retrospective study, the primary endpoints were distant recurrence (DR), locoregional recurrences (LRR), and disease-free survival (DFS). Univariate and multivariate prognostic factor analyses were carried out using survival and regression methods in the data of 704 patients with PN.


In multivariate analysis, the number of PN, ratio of PN, log odds of PN, and level III (L-III) involvement, separately, were significant factors for DR in addition to age, tumor size, and lymphovascular invasion (LVI). In the final model including all expressions of nodal involvement, age (continuous P = 0.001; hazard ratio [HR]: 0.98; 95% confidence Interval [95% CI]: 0.96–0.99), tumor size (continuous: P < 0.0001; HR: 1.3; 95% CI, 1.2–1.5), LVI (yes vs. no: P = 0.005; HR: 1.6; 95% CI, 1.2–2.2), and ratio of PN (continuous: P = 0.02; HR: 1.03; 95% CI, 1.01–1.06) were the independent prognostic factors for DR. For LRR, ratio of PN (continuous: P = 0.001; HR: 1.02; 95% CI, 1.01–1.03) was the most important factor in addition to age (continuous: P = 0.02; HR: 0.98; 95% CI, 0.97–0.99) and tumor size (continuous: P = 0.04; HR: 1.3; 95% CI, 1.1–1.6). When patients were stratified by number categories of PN (1–3 vs. 4–9 vs. ≥ 10), there was no difference between DFSs of patients with and without L-III involvement. In contrast, when patients were stratified by L-III involvement, DFSs according to the number categories were statistically different.


Ratio of PN was more valuable than number of PN for predicting outcome in node-positive breast carcinoma patients. Level III involvement was not an independent prognostic indicator either for locoregional or for distant recurrences.


  1. 1.
    Hadjiloucas I, Bundred NJ. Axillary surgery: is it necessary? Breast 2000;9:2–4PubMedCrossRefGoogle Scholar
  2. 2.
    Bembenek A, Schlag PM. Lymph node dissection in breast cancer. Langenbecks Arch Surg 2000;385:236–245PubMedCrossRefGoogle Scholar
  3. 3.
    Canavese G, Catturich A, Vecchio C, et al. Prognostic role of lymph node level involvement in patients undergoing axillary dissection for breast cancer. Eur J Surg Oncol 1998;24:104–109PubMedCrossRefGoogle Scholar
  4. 4.
    Vin-Hung V, Verschraegen C, Promish DI, et al. Ratios of involved nodes in breast cancer. Breast Cancer Res 2004;6:R680–R688CrossRefGoogle Scholar
  5. 5.
    Toma S, Leonessa F, Romanini A, et al. Predictive value of some clinical and pathological parameters on upper level axillary lymph node involvement in breast cancer. Anticancer Res 1991;11:1439–1444PubMedGoogle Scholar
  6. 6.
    Newman LA, Kuerer HM, Fornage B, et al. Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer. Am J Surg 2001;181:313–318PubMedCrossRefGoogle Scholar
  7. 7.
    Barth RJ, Danforth DN, Venzon DJ, et al. Level of axillary involvement by lymph node metastases from breast cancer is not an independent predictor of survival. Arch Surg 1991;126:574–577PubMedGoogle Scholar
  8. 8.
    Haffty BG, Ward B, Pathare P, et al. Reappraisal of the role of axillary lymph node dissection in the conservative treatment of breast cancer. J Clin Oncol 1997;15:691–700PubMedGoogle Scholar
  9. 9.
    Luini A, Zurrida S, Galimberti V, et al. Axillary dissection in breast cancer. Crit Rev Oncol Hematol 1999;30:63–70PubMedGoogle Scholar
  10. 10.
    Sinha PS, Thrush S, Bendall S,et al. Does radical surgery to the axilla give a survival advantage in more severe breast cancer? Eur J Cancer 2002;38:1474–1477PubMedCrossRefGoogle Scholar
  11. 11.
    Voss M, Schneider JW, Apffelstaedt J. Axillary lymph node involvement in stage III breast cancer: treatment implications. J Surg Oncol 1999;71:162–166PubMedCrossRefGoogle Scholar
  12. 12.
    Greene FL, Page DL, Fleming ID, et al. editors. AJCC Cancer Staging Manuel. 6th ed. Berlin Heidelberg New York: Springer, 2002Google Scholar
  13. 13.
    Megale Costa LJ, Soares HP, Gaspar HA, et al. Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol 2004;27:304–306PubMedCrossRefGoogle Scholar
  14. 14.
    Truong PT, Berthelet E, Lee J, et al. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer 2005;103:2006–2014PubMedCrossRefGoogle Scholar
  15. 15.
    Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457–481CrossRefGoogle Scholar
  16. 16.
    Cox DR. Regression models and life tables. J R Stat Soc 1972;B34:187–220Google Scholar
  17. 17.
    Kleinbaum DG, Kupper LL, Muller KE, et al. editors. Applied Regression Analysis and Other Multivariable Methods, 3rd edn. Pacific Grove: Brooks/Cole, 1998Google Scholar
  18. 18.
    Harrell FE Jr. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. Berlin Heidelberg New York: Springer, 2001Google Scholar
  19. 19.
    Schemper M. Predictive accuracy and explained variation. Stat Med 2003;22:2299–2308PubMedCrossRefGoogle Scholar
  20. 20.
    Hanley JA, McNeil BJ. The meaning and use of the area under a receiver characteristic (ROC) curve. Radiology 1982;143:29–36PubMedGoogle Scholar
  21. 21.
    Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32–35PubMedCrossRefGoogle Scholar
  22. 22.
    Moore MP, Kinne DW. Axillary lymphadenectomy: a diagnostic and therapeutic procedure. J Surg Oncol 1997;66:2–6PubMedCrossRefGoogle Scholar
  23. 23.
    Jansen RLH, Hillen HFP, Schouten HC. Prognostic and predictive factors in breast cancer. Netherlands J Med 1997;51:65–77CrossRefGoogle Scholar
  24. 24.
    Joslyn SA, Konety BR. Effect of axillary lymphadenectomy on breast carcinoma survival. Breast Cancer Res Treat 2005;91:11–18PubMedCrossRefGoogle Scholar
  25. 25.
    Sakorafas GH, Tsiotou AG, Balsiger BM. Axillary lymph node dissection in breast cancer. Acta Oncol 2000;39:455–466PubMedCrossRefGoogle Scholar
  26. 26.
    Saha S, Farrar WB, Young DC, et al. Variation in axillary node dissection influences the degree of nodal involvement in breast cancer patients. J Surg Oncol 2000;73:134–137PubMedCrossRefGoogle Scholar
  27. 27.
    Recht A. Nodal treatment for patients with early stage breast cancer: guilty or innocent? Radiother Oncol 1992;25:79–82PubMedCrossRefGoogle Scholar
  28. 28.
    Yildirim E, Soydinc P, Yildirim N, et al. Role of increased arterial inflow in arm edema after modified radical mastectomy. J Exp Clin Cancer Res 2000;19:427–430PubMedGoogle Scholar
  29. 29.
    Chua B, Ung O, Taylor R, et al. Is there a role for axillary dissection for patients with operable breast cancer in this era of conservatism? ANZ J Surg 2002;72:786–792PubMedCrossRefGoogle Scholar
  30. 30.
    Petrek JA, Heelan MC. Incidence of breast carcinoma related lymphedema. Cancer 1998;83:2776–2781PubMedCrossRefGoogle Scholar
  31. 31.
    Liljegren G, Holmberg L. Arm morbidity after sector resection, axillary dissection with or without postoperative radiotherapy in breast cancer stage I: results from a randomized trial—Uppsala–Orebro Breast Cancer Study Group. Eur J Cancer 1997;33:193–199PubMedCrossRefGoogle Scholar
  32. 32.
    Kuehn T, Klas W, Darsow M, et al. Long-term morbidity following axillary dissection in breast cancer patients: clinical assessment, significance for life quality and the impact of demographic, oncologic, and therapeutic factors. Breast Cancer Res Treat 2000;64:275–286PubMedCrossRefGoogle Scholar
  33. 33.
    Taylor KO. Morbidity associated with axillary surgery for breast cancer. ANZ J Surg 2004;74:314–317PubMedCrossRefGoogle Scholar
  34. 34.
    Somner JEA, Dixon JMJ, Thomas JSJ. Node retrieval in axillary lymph node dissections: recommendations for minimum numbers to be confident about node negative status. J Clin Pathol 2004;57:845–848PubMedCrossRefGoogle Scholar
  35. 35.
    Blichert-Toft M. Axillary surgery in breast cancer management. Acta Oncol 2000;39:269–275PubMedCrossRefGoogle Scholar
  36. 36.
    Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG).. Eur J Cancer 1992;28A:1415–1418PubMedCrossRefGoogle Scholar
  37. 37.
    Petrik DW, McCready DR, Sawka CA, Goel V. Association between extent of axillary lymph node dissection and patient, tumor, surgeon, and hospital factors in patients with early breast cancer. J Surg Oncol 2003;82:84–90PubMedCrossRefGoogle Scholar
  38. 38.
    Cady B. A contemporary view of axillary dissection. Ann Surg 2000;232:8–9PubMedCrossRefGoogle Scholar
  39. 39.
    Rutgers EJ, EUSOMA Consensus Group. Quality control in the locoregional treatment of breast cancer. Eur J Cancer 2001;37:447–453PubMedCrossRefGoogle Scholar
  40. 40.
    Rutgers EJ. Guidelines to assure quality in breast cancer surgery. Eur J Surg Oncol 2005;31:568–576PubMedCrossRefGoogle Scholar
  41. 41.
    Sosa JA, Diener-West M, Gusev Y, et al. Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer. Ann Surg Oncol 1998;5:140–149PubMedCrossRefGoogle Scholar
  42. 42.
    Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Clin Oncol 2001;19:3817–3827PubMedGoogle Scholar
  43. 43.
    Goldhirsch A, Glick JH, Gelber RD, et al, and panel members. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569–1583PubMedCrossRefGoogle Scholar
  44. 44.
    Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1539–1569PubMedGoogle Scholar
  45. 45.
    Kingsmore DB, Ssemwogerere A, Hole DJ, et al. Increased mortality from breast cancer and inadequate axillary treatment. Breast 2003;12:36–41PubMedCrossRefGoogle Scholar
  46. 46.
    Gervasoni JE, Taneja C, Chung MA, et al. Axillary dissection in the context of the biology of lymph node metastases. Am J Surg 2000;180:278–283PubMedCrossRefGoogle Scholar
  47. 47.
    Pierce LJ. The use of radiotherapy after mastectomy: A review of the literature. J Clin Oncol 2005;23:1706–1717PubMedCrossRefGoogle Scholar
  48. 48.
    Recht A, Gray R, Davidson NE, et al. Locoregional failure ten years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol 1999;17:1689–1700PubMedGoogle Scholar
  49. 49.
    Senofsky GM, Moffat FL, Davis K, et al. Total axillary lymphadenectomy in the management of breast cancer. Arch Surg 1991;126:1336–1342PubMedGoogle Scholar
  50. 50.
    Siegel BM, Mayzel KA, Love SM. Level I and II axillary dissection in the treatment of early stage breast cancer. An analysis of 259 consecutive patients. Arch Surg 1990;125:1144–1147PubMedGoogle Scholar
  51. 51.
    Arriagada R, Rutqvist LE, Mattsson A, et al. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clin Oncol 1995;13:2869–2878PubMedGoogle Scholar
  52. 52.
    Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b Trial. N Eng J Med 1997;337:949–955CrossRefGoogle Scholar
  53. 53.
    Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Eng J Med 1997;337:956–962CrossRefGoogle Scholar
  54. 54.
    Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high–risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group 82c randomized trial. Lancet 1999;353:1641–1648PubMedCrossRefGoogle Scholar
  55. 55.
    Whelan TJ, Julian J, Wright J, et al. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 2000;18:1220–1229PubMedGoogle Scholar
  56. 56.
    Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia Randomized Trial. J Natl Cancer Inst 2005;97:116–126PubMedCrossRefGoogle Scholar
  57. 57.
    Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicine-based chemotherapy: Implications for postoperative irradiation. J Clin Oncol 2000;18:2817–2827PubMedGoogle Scholar
  58. 58.
    Beenken SW, Urist MM, Zhang Y, et al. Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer. Ann Surg 2003;237:732–739PubMedCrossRefGoogle Scholar
  59. 59.
    Fisher B, Anderson S, Bryant J, et al. Twenty-year follow up of randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Eng J Med 2002;347:1233–1241CrossRefGoogle Scholar
  60. 60.
    Deckers PJ. Axillary dissection in breast cancer: when, why, how much, and for how long? Another operation soon to be extinct? J Surg Oncol 1991;48:217–219PubMedGoogle Scholar
  61. 61.
    Henderson IC. Axillary surgery: clinical judgment required. J Clin Oncol 2006;24:325–326PubMedCrossRefGoogle Scholar
  62. 62.
    Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival: a Bayesian metaanalysis. Ann Surg Oncol 1999;61:109–116CrossRefGoogle Scholar
  63. 63.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087–2106Google Scholar
  64. 64.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–1717CrossRefGoogle Scholar
  65. 65.
    Olivotto IA, Truong PT. Postmastectomy radiation therapy: who needs it? J Clin Oncol 2004;22:4237–4239PubMedCrossRefGoogle Scholar
  66. 66.
    Parmigiani G, Berry DA, Winer EP, et al. Is axillary lymph node dissection indicated for early stage breast cancer? A decision analysis. J Clin Oncol 1999;17:1465–1473PubMedGoogle Scholar
  67. 67.
    Schrenk P, Rieger R, Shamiyeh A, et al. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000;88:608–614PubMedCrossRefGoogle Scholar
  68. 68.
    Louis-Sylvestre C, Clough K, Asselain B, et al. Axillary treatment in conservative management of operable breast cancer: Dissection or radiotherapy? Results of a randomized study with 15 years of follow up. J Clin Oncol 2004;22:97–101PubMedCrossRefGoogle Scholar
  69. 69.
    Katz A, Strom EA, Buchholz TA, et al. The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys 2001;50:735–742PubMedCrossRefGoogle Scholar
  70. 70.
    Wallgren A, Bonetti M, Gelber RD, et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I Through VII. J Clin Oncol 2003;21:1205–1213PubMedCrossRefGoogle Scholar
  71. 71.
    Voogd AC, Nielsen M, Peterse JL, et al., Danish Breast Cancer Cooperative Group, Breast Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 2001;19:1688–1697PubMedGoogle Scholar
  72. 72.
    Woodward WA, Strom EA, Tucker SL, et al. Locoregional recurrence after doxorubicine-based chemotherapy and postmastectomy implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys 2003;57:336–344PubMedCrossRefGoogle Scholar
  73. 73.
    Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy. Results of five National Surgical Adjuvant Breast and Bowel Project Randomized Clinical Trials. J Clin Oncol 2004;22:4247–4254PubMedCrossRefGoogle Scholar
  74. 74.
    Jager JJ, Volovics L, Schouten LJ, et al. Locoregional recurrences after mastectomy in breast cancer: prognostic factors and implications for postoperative irradiation. Radiother Oncol 1999;50:267–275PubMedCrossRefGoogle Scholar
  75. 75.
    Fisher BJ, Perera FE, Cooke AL, et al. Long-term follow-up axillary node-positive breast cancer patients receiving adjuvant systemic therapy alone: patterns of recurrence. Int J Radiat Oncol Biol Phys 1997;38:541–550PubMedCrossRefGoogle Scholar
  76. 76.
    Cheng JCH, Chen CM, Liu MC, et al. Locoregional failure of postmastectomy patients with 1–3 positive axillary lymph nodes without adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2002;52:980–988PubMedCrossRefGoogle Scholar
  77. 77.
    Gruber G, Bonetti M, Nasi ML, et al. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long–term observations from International Breast Cancer Study Group Trial VI. J Clin Oncol 2005;23:7089–7097PubMedCrossRefGoogle Scholar
  78. 78.
    Katz A, Buchholz TA, Thames H, et al. Recursive partitioning analysis of locoregional recurrence patterns following mastectomy: implication for adjuvant irradiation. Int J Radiat Oncol Biol Phys 2001;50:397–403PubMedCrossRefGoogle Scholar
  79. 79.
    Van der Wal BCH, Butzelaar RMJM, van der Meij S, et al. Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol 2002;28:481–489PubMedCrossRefGoogle Scholar
  80. 80.
    Voordeckers M, Vinh-Hung V, Van de Sten J, et al. The lymph node ratio as prognostic factor in node positive breast cancer. Radiother Oncol 2004;70:225–230PubMedCrossRefGoogle Scholar
  81. 81.
    Haris JR, Halpin-Murphy P, McNeese M, et al. Consensus statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 1999;44:989–990CrossRefGoogle Scholar
  82. 82.
    Van der Hage JA, Putter H, Bonnema J, et al., EORTC Breast Cancer Group. Impact of locoregional treatment on the early-stage breast cancer patients: a retrospective analysis. Eur J Cancer 2003;39:2192–2199PubMedCrossRefGoogle Scholar
  83. 83.
    Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004;240:306–312PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2007

Authors and Affiliations

  1. 1.Ankara Oncology Training and Research HospitalAnkaraTurkey
  2. 2.AnkaraTurkey

Personalised recommendations